Pharmaceutical Technology Europe-10-01-2008

Pharmaceutical Technology Europe
Spotlight

October 01, 2008

In the popular view of nanomedicine, miniature robots equipped with a set of tools will one day patrol the inside of the body, cleaning up atheroslerotic plaque, zapping cancer cells, and generally performing repair and maintenance.

Pharmaceutical Technology Europe

Emerging technologies now enable continuous on-line monitoring and control of ozone systems, providing precise and reliable results, revolutionizing the way dissolved ozone is measured.

Pharmaceutical Technology Europe

The design of accurate and robust analytical methodology is instrumental to developing orally inhaled and nasal drug products (OINDPs) and their appropriate control programmes.

Pharmaceutical Technology Europe
PAT

October 01, 2008

The biggest benefit of PAT and the current FDA initiatives may be in allowing pharmaceutical scientists to use their technical capabilities to improve pharmaceutical processes.

Pharmaceutical Technology Europe
Viewpoint

October 01, 2008

The most public argument against direct-to-consumer advertising in Europe is essentially paternalistic: to protect people from companies who are considered unable to present an objective account of their drugs.

Pharmaceutical Technology Europe
Pushing for allergen labelling

October 01, 2008

The biggest benefit that has been brought about by the compulsory labelling of allergens in food is the greater degree of cooperation that has been established between food manufacturers and their suppliers.

Pharmaceutical Technology Europe
Business

October 01, 2008

The days of a 'job for life' at a Big Pharma company seem to be well behind us, whether we're at the bench or in the boardroom, but that doesn't mean we should view the employment landscape with trepidation.

Pharmaceutical Technology Europe
20th Anniversary Special feature

October 01, 2008

Nanoparticles can also cross the blood–brain barrier, which could make them useful for delivering drugs that target brain tumours or diseases that affect the central nervous system.

Pharmaceutical Technology Europe

October 01, 2008

Counterfeiting has become the topic of conversation at all levels of the pharmaceutical industry. Considering the rising number of cases, this is hardly surprising.

Talking Point
Pharmaceutical Technology Europe

October 01, 2008

The potent nature of HPAPIs means there must be careful evaluation of the compound for its level of toxicity when considering manufacture.

Pharmaceutical Technology Europe
Formulation

October 01, 2008

The use of PVA copolymer-based film can solve the problems associated with lack of film adhesion... to tablets containing large amounts of waxy excipient or a lubricant.

Pharmaceutical Technology Europe
Biopharmaceuticals

October 01, 2008

...an uninformed decision based on commercial requirements alone may, ultimately, have disastrous consequences on the efficacy of the target recombinants.

Pharmaceutical Technology Europe
Outsourcing review

October 01, 2008

CMOs must find new business models and strategies that reflect the many dimensions of the industry's realities...